Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Share Class Description:
NKTR: Ordinary SharesCompare
Compare
Traded in other countries / regions
NKTR.USAITH0.GermanyNKTR.Mexico0UNL.UK Index Membership
Russell 2000Russell 3000S&P 500Russell 3000Russell 2000 IPO Date
1994-05-03Description
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.18 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 7.3 | |||||
| Debt-to-EBITDA | -1.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -19.39 | |||||
| Beneish M-Score | -3.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.9 | |||||
| 3-Year EBITDA Growth Rate | 44.9 | |||||
| 3-Year EPS without NRI Growth Rate | 37.2 | |||||
| 3-Year FCF Growth Rate | 28.3 | |||||
| 3-Year Book Growth Rate | -55.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -27.72 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.93 | |||||
| 9-Day RSI | 69.31 | |||||
| 14-Day RSI | 69.25 | |||||
| 3-1 Month Momentum % | 13.68 | |||||
| 6-1 Month Momentum % | -22.1 | |||||
| 12-1 Month Momentum % | -40.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | |||||
| Quick Ratio | 3.24 | |||||
| Cash Ratio | 3.08 | |||||
| Days Inventory | 257.06 | |||||
| Days Sales Outstanding | 8.39 | |||||
| Days Payable | 175.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 4.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.61 | |||||
| Operating Margin % | -160.27 | |||||
| Net Margin % | -152.49 | |||||
| EBITDA Margin % | -112.29 | |||||
| FCF Margin % | -204.23 | |||||
| ROE % | -201.73 | |||||
| ROA % | -41.38 | |||||
| ROIC % | -195.38 | |||||
| 3-Year ROIIC % | -110.51 | |||||
| ROC (Joel Greenblatt) % | -534.86 | |||||
| ROCE % | -38.98 | |||||
| Years of Profitability over Past 10-Year | 1 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.11 | |||||
| PB Ratio | 23 | |||||
| Price-to-Tangible-Book | 23 | |||||
| EV-to-EBIT | -1.85 | |||||
| EV-to-EBITDA | -1.91 | |||||
| EV-to-Revenue | 2.14 | |||||
| EV-to-Forward-Revenue | 4.13 | |||||
| EV-to-FCF | -1.05 | |||||
| Price-to-GF-Value | 2.16 | |||||
| Price-to-Median-PS-Value | 0.42 | |||||
| Earnings Yield (Greenblatt) % | -54.05 | |||||
| FCF Yield % | -56.25 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers